RT Journal Article SR Electronic T1 18F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1528 OP 1534 DO 10.2967/jnumed.112.116921 VO 54 IS 9 A1 Edwin A. Usmanij A1 Lioe-Fee de Geus-Oei A1 Esther G.C. Troost A1 Liesbeth Peters-Bax A1 Erik H.F.M. van der Heijden A1 Johannes H.A.M. Kaanders A1 Wim J.G. Oyen A1 Olga C.J. Schuurbiers A1 Johan Bussink YR 2013 UL http://jnm.snmjournals.org/content/54/9/1528.abstract AB The potential of 18F-FDG PET changes was evaluated for prediction of response to concomitant chemoradiotherapy in patients with locally advanced non–small cell lung cancer (NSCLC). Methods: For 28 patients, 18F-FDG PET was performed before treatment, at the end of the second week of treatment, and at 2 wk and 3 mo after the completion of treatment. Standardized uptake value (SUV), maximum SUV, metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were obtained. Early metabolic changes were defined as fractional change (ΔTLG) when 18F-FDG PET at the end of the second week was compared with pretreatment 18F-FDG PET. In-treatment metabolic changes, as measured by serial 18F-FDG PET, were correlated with standard criteria of response evaluation of solid tumors by means of CT imaging (Response Evaluation Criteria In Solid Tumors 1.1). Parameters were analyzed for stratification in progression-free survival (PFS). Results: When compared with early metabolic nonresponders, a ΔTLG decrease of 38% or more was associated with a significantly longer PFS (1-y PFS 80% vs. 36%, P = 0.02). Pretreatment TLG was found to be a prognostic factor for PFS. Conclusion: The degree of change in TLG was predictive for response to concomitant chemoradiotherapy as early as the end of the second week into treatment for patients with locally advanced NSCLC. Pretreatment TLG was prognostic for PFS.